Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy
Open Access
- 9 June 2016
- journal article
- research article
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 117 (1) , 41-51
Abstract
Single-dose human fibrinogen concentrate (FCH) might have haemostatic benefits in complex cardiovascular surgery. Patients undergoing elective aortic surgery requiring cardiopulmonary bypass were randomly assigned to receive FCH or placebo. Study medication was administered to patients with a 5 min bleeding mass of 60–250 g after separation from bypass and surgical haemostasis. A standardized algorithm for allogeneic blood product transfusion was followed if bleeding continued after study medication. 519 patients from 34 centres were randomized, of whom 152 (29%) met inclusion criteria for study medication. Median (IQR) pretreatment 5 min bleeding mass was 107 (76–138) and 91 (71–112) g in the FCH and placebo groups, respectively (P=0.13). More allogeneic blood product units were administered during the first 24 h after FCH, 5.0 (2.0–11.0), when compared with placebo, 3.0 (0.0–7.0), P=0.026. Fewer patients avoided transfusion in the FCH group (15.4%) compared with placebo (28.4%), P=0.047. The FCH immediately increased plasma fibrinogen concentration and fibrin-based clot strength. Adverse event rates were comparable in each group. Human fibrinogen concentrate was associated with increased allogeneic blood product transfusion, an unexpected finding contrary to previous studies. Human fibrinogen concentrate may not be effective in this setting when administered according to 5-minute bleeding mass. Low bleeding rates and normal-range plasma fibrinogen concentrations before study medication, and variability in adherence to the complex transfusion algorithm, may have contributed to these results. ClinicalTrials.gov identifier no. NCT01475669; EudraCT trial no. 2011-002685-20.Keywords
Funding Information
- CSL Behring GmbH
This publication has 22 references indexed in Scilit:
- Safety of fibrinogen concentrate: analysis of more than 27 years of pharmacovigilance dataThrombosis and Haemostasis, 2015
- Randomized, Double‐Blinded, Placebo‐Controlled Trial of Fibrinogen Concentrate Supplementation After Complex Cardiac SurgeryJournal of the American Heart Association, 2015
- Cryoprecipitate therapyBritish Journal of Anaesthesia, 2014
- The effects of pre- and postoperative fibrinogen levels on blood loss after cardiac surgery: a systematic review and meta-analysisInteractive CardioVascular and Thoracic Surgery, 2013
- Perioperative factor concentrate therapyBritish Journal of Anaesthesia, 2013
- Adverse effects of plasma transfusionTransfusion, 2012
- Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgeryBritish Journal of Anaesthesia, 2010
- Thromboelastometry-guided administration of fibrinogen concentrate for the treatment of excessive intraoperative bleeding in thoracoabdominal aortic aneurysm surgeryThe Journal of Thoracic and Cardiovascular Surgery, 2009
- Plasma fibrinogen level, bleeding, and transfusion after on‐pump coronary artery bypass grafting surgery: a prospective observational studyTransfusion, 2008
- Hemostatic Factors and Replacement of Major Blood Loss with Plasma-Poor Red Cell ConcentratesAnesthesia & Analgesia, 1995